INN or brand name drug prescriptions: a multilevel, cross-sectional study in general practice.
Adolescent
Cross-Sectional Studies
Drug Prescriptions
/ statistics & numerical data
Drugs, Generic
/ therapeutic use
Female
France
General Practice
/ statistics & numerical data
Health Expenditures
/ statistics & numerical data
Humans
Male
Multivariate Analysis
Practice Patterns, Physicians'
/ statistics & numerical data
Prescription Drugs
/ therapeutic use
Brand name
Drug prescription
General practice
International Nonproprietary Name (INN)
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
19
08
2018
accepted:
19
10
2018
pubmed:
29
10
2018
medline:
10
5
2019
entrez:
29
10
2018
Statut:
ppublish
Résumé
The prescription in International Nonproprietary Names (INN) is a legal obligation for all physicians in France since January 2015. The objective of this study was to analyze the frequency and main factors of INN drug prescribing in general practice. Multicenter cross-sectional study conducted with 11 interns acting as observers of 23 GP trainers between November 2015 and January 2016. Two evaluators analyzed all GPs' drug prescriptions to identify INN or brand name prescriptions. The database included 4957 drugs prescribed during 1647 visits. Of these, 1462 (29.5% [95% CI 28.2-30.8%]) were prescribed only in INN. According to the multivariate analyses, the factors favoring INN prescribing were as follows: at the drug level, its initial prescribing (OR = 1.4), a nonspecific prescribing objective (OR = 1.6), its listing in the generic drug index with (OR = 7.7) or without (OR = 2.9) efficiency objective included in the payment for public health objectives (PPHO) program, and the oral route of administration (OR from 0.4 for the percutaneous route to 0.2 for the pulmonary route); at the patient level, the male gender (OR = 1.3), the age of 15 years or more (OR = 1.9), and the absence of a long-term condition (OR = 1.3); at the physician level, the reception of a public healthcare insurance representative (OR = 4.1), the nonreception of pharmaceutical sales representatives (OR = 3.0), and the urban practice environment (OR = 2.8). In 2015, less than one third of drugs were prescribed in INN only in general practice. The use of various incentives and regulatory measures is likely to favor the prescription of INNs by practitioners.
Identifiants
pubmed: 30368571
doi: 10.1007/s00228-018-2580-8
pii: 10.1007/s00228-018-2580-8
doi:
Substances chimiques
Drugs, Generic
0
Prescription Drugs
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-283Références
Expert Opin Drug Saf. 2004 May;3(3):167-72
pubmed: 15155145
Med J Malaysia. 2008 Oct;63(4):315-8
pubmed: 19385492
Health Policy. 2011 Feb;99(2):139-48
pubmed: 20732723
J Am Med Inform Assoc. 2010 Nov-Dec;17(6):681-8
pubmed: 20962131
Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):185-91
pubmed: 21254290
Health Policy. 2012 Mar;104(3):247-52
pubmed: 22217861
BMC Pharmacol Toxicol. 2013 Jan 05;14:1
pubmed: 23289757
Indian J Pharmacol. 2013 May-Jun;45(3):252-7
pubmed: 23833368
Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):469-82
pubmed: 23977975
Int J Med Inform. 2014 Jan;83(1):47-56
pubmed: 24168761
J Pharm Pharm Sci. 2013;16(4):511-29
pubmed: 24210060
J Rural Health. 2014 Summer;30(3):235-43
pubmed: 24528129
PLoS One. 2014 Oct 03;9(10):e104828
pubmed: 25279555
BMC Med Educ. 2016 Apr 27;16:126
pubmed: 27117188
JAMA Intern Med. 2016 Jun 1;176(6):763-8
pubmed: 27159336
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):819-826
pubmed: 28485111
Intern Med J. 2017 Aug;47(8):959-962
pubmed: 28782212
BMJ Open. 2017 Sep 27;7(9):e016408
pubmed: 28963287
Pediatr Infect Dis J. 1996 Jan;15(1):18-22
pubmed: 8684871